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Objectives: In April 2010, the National Collegiate Athletic Association (NCAA) 
approved mandatory testing for sickle cell trait status for all student athletes participating in 
Division I sports. Children’s Sickle Cell Program at Children’s Hospital of Pittsburgh offered 
genetic testing and counseling to all student athletes participating in Division I athletes at the 
University of Pittsburgh and Duquesne University.   
Methods: To assess the knowledge of sickle cell trait among the student athletes, along 
with the effect of genetic counseling, student athletes were asked to participate in a survey. A 
short survey was provided to the student athletes prior to their genetic counseling, with a short 
survey provided following the genetic testing (See Appendix A for IRB consent form and 
Appendix B for questionnaires).   
Results: Between the two Division I programs at the University of Pittsburgh and 
Duquesne University, 122 student athletes were tested of which, one athlete was diagnosed with 
sickle cell trait. Among the 122 student athletes tested, 80 participated in the surveys. Among 
those who participated, 57 (71%) were Caucasian, 16 (20%) were African American, and the 
remaining athletes were of mixed or other ethnic backgrounds. Prior to the genetic counseling 
session, 11% of the student athletes answered that they had never heard of sickle cell disease or 
sickle cell trait. Following the genetic counseling session, 89% of the student athletes had a good 
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understanding of sickle cell trait, with 15% showing that they learned something from the 
genetic counseling session. 
Conclusions: Based on the data obtained from this study, student athletes may not have a 
good understanding of the testing that is mandated by the NCAA.  Therefore, genetic counseling 
is strongly recommended to all student athletes prior to carrier status testing.  
Implications for Public Health: The NCAA has been criticized for their ruling 
mandating sickle cell trait testing.  However, many are not focusing on the importance of the 
impact genetic testing has on an individual, particularly this age range involved.  Genetic 
counseling needs to be considered when requiring these student athletes to undergo genetic 
testing for sickle cell trait.   
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1.0  INTRODUCTION 
In the United States, the prevalence of SCT among African Americans is about 8%, or 1 in 12 
African Americans.  Sickle cell trait, or sickle cell carriers, are characterized by the presence of 
both Hb A and Hb S, given them the genotype Hb AS.  Studies performed over the years have 
focused on the association between sickle cell trait and exertional exercise.  Studies, first from 
the military, then on athletes across high school and collegiate sports, have demonstrated a link 
between unexplained sudden death related to exercise and sickle cell trait.   
Individuals with sickle cell trait are typically thought of as being asymptomatic with a 
normal life span.  Some studies show that individuals with sickle cell trait may actually be at a 
slightly increased risk for splenic infarction, exertional rhabdomyolysis, and exercise-related 
sudden death.1  It is hypothesized that if an athlete has sickle cell trait, intense exercise can cause 
changes in the body know n to cause sickling, also known as exertional sickling.  Exertional 
sickling can lead to rapid muscle break down, called rhabdomyolysis, which can be fatal.   
In April 2010, the National Collegiate Athletic Association (NCAA) approved mandatory 
testing for sickle cell trait status for all student athletes participating in Division I sports.  This 
was a ch ange from previous years, in which sickle cell trait testing was recommended, and 
offered on a voluntary basis, at the discretion of individual athletic programs.  To accommodate 
local Pittsburgh, PA universities, including the University of Pittsburgh and Duquesne 
University, the Children’s Sickle Cell Program and Children’s Hospital of Pittsburgh offered 
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genetic testing and counseling to student athletes at the University of Pittsburgh.  In an attempt to 
expand our program, the aim of this study was to extend our contact to other local Pittsburgh 
universities and offer genetic counseling and testing services to their student athletes.  T his 
project was successive in expanding our services to include the University of Pittsburgh and 
Duquesne University Athletic Departments.  Genetic counseling and testing was provided to all 
student athletes willing to participate.  Questionnaires (Appendix B) were administrated to those 
student athletes willing to participate in that particular part of the study. A pre-counseling 
questionnaire was offered to the student athletes prior to their counseling session, which 
contained basic knowledge of sickle cell disease and sickle cell trait.  Following the genetic 
counseling session and the blood test for sickle cell trait, a post-counseling questionnaire was 
offered to the student athletes, containing similar questions as those found on the pre-counseling 
questionnaire.   The aim of the questionnaires was to gain a better understanding of the prior 
knowledge of sickle cell disease and sickle cell trait, along with the effectiveness of the genetic 
counseling provided to the student athletes.  Our ultimate goal is to bring awareness of sickle cell 
trait to the athletic community and emphasize the importance of genetic counseling in 
association with genetic testing.   
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2.0  SPECIFIC AIMS 
2.1 SPECIFIC AIM 1 
Specific Aim I: To provide sickle cell trait testing to student athletes. 
 
The first aim of this study was to provide sickle cell trait testing to student athletes 
participating in Division I sports teams at the University of Pittsburg and Duquesne University.  
Compliance with the NCAA ruling passed in April 2010, and effective August 2010 w as 
followed to allow for timely and effective testing of student athletes.   
2.2 SPECIFIC AIM 2 
Specific Aim 2: To provide counseling and education to student athletes on sickle cell trait and 
the potential complications associated with sickle cell trait in athletes. 
 
The second aim of this study was to provide genetic counseling and education to student 
athletes prior to undergoing genetic testing for sickle cell trait.  Counseling and education 
material were aimed at the proposed physiology of exertional sickling related to sickle cell trait 
in athletes along with the signs and symptoms and forms of prevention.    
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2.3 SPECIFIC AIM 3 
Specific Aim 3: To survey the student athletes in order to obtain information and evaluate the 
counseling offered along with the impact the new NCAA ruling has on the student athletes. 
 
The third aim of this study was to provide the student athletes with questionnaires prior to 
and following genetic counseling and genetic testing for sickle cell trait.  This aim was to assess 
the general knowledge of sickle cell disease and sickle cell trait.  This aim was also to obtain the 
effectiveness of the genetic counseling along with the experience of undergoing genetic 
counseling and genetic testing in the athletic setting.   
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3.0  BACKGROUND AND SIGNIFICANCE 
In humans, hemoglobin is a globular protein molecule1 comprised of alpha and beta globin 
chains.  The α-globin chain is located on chromosome 16 and codes for the adult α-globin and 
the ζ-globin chain, which is the embryonic form of α-globin.  The β-globin chain is located on 
chromosome 11.   At this location, four genes are present, which include the embryonic ε gene, 
the fetal γ gene, the adult δ gene, and the adult βgene.1  These four types of hemoglobin are 
expressed differently at particular times of our development.  Figure 1 demonstrates the timeline 
of the expression of the human globin genes from the early stages of fetal development to the 
changes that occur at birth and the first year of life. 
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Figure 1: Timeline of the expression of the human globin genes 
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Over 400 types of hemoglobin exist.  The most common hemoglobins include Hb A, Hb 
A2, Hb S, Hb C, Hb F, Hb D Punjab (or D Los Angeles), and Hb O Arab
4
 (Table 1). 
 
Table 1: Types of Hemoglobin (Adapted from Serjeant4). 
Hb A α2β2 
Hb A2 α2δ2 
Hb S Glutamic acid (GAG)  valine (GTG) at position β6 
Hb C Glutamic acid (GAG)  lysine (AAG) at position β6 
Hb F α2γ2 
Hb D Punjab 
(or D Los Angeles) 
Glutamic acid (GAG)  glutamine (CAG) at position β121 
Hb O Arab Glutamic acid (GAG)  lysine (AAG) at position β121 
HbE Glutamic acid (GAG)  lysine (AAG) at position β26 
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3.1 SICKLE CELL DISEASE 
Sickle cell disease is an autosomal recessive genetic blood disorder that predominately affects 
persons of African ancestry.3  However, sickle cell disease can also affects persons of 
Mediterranean, Caribbean, South and Central American, Arabian, and East Indian ancestry.3  
James B. Herrick first described sickle cell disease in 1910, with his identification of abnormally 
shaped red blood cells, which he identified as sickle-shaped, giving the disease its name.   
Sickle cell disease is defined by   the presence of Hemoglobin S (Hb S).  Sickle 
Hemoglobin (Hb S) is an example of a single point mutation involving GAG  GTG 
transversion at codon 6 of  the β-globin gene.1,4This single point mutation causes a change in 
amino acid at position 6 in the β-globin chain from glutamic acid to valine.  The position of this 
change is located on the surface of the hemoglobin molecule.  The replacement of glutamic acid 
with valine results in a change in the characteristics of the deoxygenated Hb S, causing Hb S to 
become much less soluble than Hb A.  When Hb S becomes deoxygenated, polymerization of Hb 
S occurs in erythrocytes.  The polymer takes on the form of an elongated rope-like fiber or rigid 
tubule,5,6,7causing a change in shape from the smooth, doughnut-shaped red blood cells5to 
hallmark sickle-shape cells.  Sickle-shaped cells are stiff and sticky and can cause blockages in 
the small blood vessels.5  When this occurs, an adequate blood supply may not be able to reach 
organs and tissues, resulting in damage to these particular organs or tissues.3  The 
Pathophysiology of sickle cell disease can be illustrated in Figure 2.8 
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Figure 2: Pathophysiology of sickle-cell disease8 
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Hb SS is the most common form of sickle cell disease and is believed to affect more than 
50,000 Americans.  Sickle cell disease is most common among individuals of African descent; 
however, individuals of Mediterranean, Caribbean, South and Central America, Arabian, and 
East Indian descent may also be affected.  The estimated prevalence of Hb SS among African 
American live births is believed to be one out of every 375 live births, while the estimated 
prevalence of Hb SC among African American live births is believed to be one out of every 835 
live births.  Due to the prevalence of sickle cell disease, it is believed that approximately 8% or 1 
in 12 of  the African American population in the United States carry Hb S, giving them the 
diagnosis of sickle cell trait.3 
Sickle cell disease can also occur when an individual inherits hemoglobin S from one 
parent and hemoglobin C from the other parent, denoted Hb SC.  Hb SC disease is less common 
than Hb SS disease among the African American population.9  H b C does not participate9 in 
polymerization with deoxygenated Hb;10,11 however, the presence of Hb C within the cell does 
lead to enhanced and sustained potassium and chloride cotransport.10  T he loss of potassium 
causes the erythrocytes to become dehydrated, which in turn leads to an increased concentration 
of Hb S erythrocytes.10  Depending on the levels, polymerization and sickling are likely to occur.   
Individuals with Hb SC disease may demonstrate clinical symptoms similar to those seen 
in Hb SS disease.  Some studies demonstrate that the symptoms of Hb SC disease may be less 
severe than Hb SS.   There appears to be much variation among individuals with both Hb SS and 
Hb SC disease.12,13  Individuals with Hb SC disease are at risk for the same life-threatening 
complications as those with Hb SS disease.  Complications may occur less frequently in Hb SC 
disease than they appear to in Hb SS disease.12,13 
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            3.1.1 Inheritance 
Sickle cell disease is an autosomal recessive condition and occurs when an individual inherits an 
abnormal hemoglobin gene from both parents.  If an individual has one sickle cell gene and one 
normal βA-chain gene,4 they have what is known as sickle cell trait.  If both parents have an 
abnormal hemoglobin gene, in each pregnancy, the couple would have a 25% or 1 in 4 chance of 
both passing on their abnormal hemoglobin gene, resulting in a child with hemoglobin disease.   
            3.1.2 Clinical Manifestations 
The clinical hallmarks of sickle cell disease include vaso-occlusive phenomena and hemolysis.14  
Vaso-occlusive phenomena, previously known called sickle cell crisis, is the occlusion of a 
blood vessel,8 resulting in recurrent painful episodes.  Hemolysis is a variety of serious organ 
system complications that can lead to life-long disabilities and/or early death.14Other 
complications that are typically associated with sickle cell disease include anemia, dactylitis, 
acute pain episodes, splenic sequestration, and vaso-occlusion in any organ system.14 
            3.1.2.1 Blood 
Acute painful episodes, previously called sickle cell crisis, are the most common type of vaso-
occlusive event that occurs in sickle cell disease.  These episodes are the most frequent symptom 
individuals with sickle cell disease experience and it is usually the reason individuals seek 
medical attention.1,15,16  There is a great deal of variability among individuals with sickle cell 
disease when it comes to the severity, frequency, location, and duration of episodes.1,17,18  Some 
studies show that the frequency of episodes may peak around the ages 19-39.19  These pain 
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episodes may be triggered by a  number of events, including, weather conditions, dehydration, 
infection, stress, menses, alcohol consumption, nocturnal hypoxemia, and obstructive sleep 
apnea.20-25  Examples of weather conditions that may prompt pain episodes include cold 
temperatures, high wind speed, low humidity, and atmospheric pollutants.1,26-28 
Sickle cell patients experiencing an acute painful episode, tend to experience pain 
primarily in the upper back (63%) or the left arm (61%).29  Patients with sickle cell disease may 
also experience pain in their legs (38%), chest (26%), or lower back (12%).29  Individuals 
experiencing an acute painful episode may exhibit clinical signs, such as a fever, swelling or 
tenderness in the region of the vaso-occlusion, tachypnea, hypertension, and nausea or vomiting.1 
The majority of individuals with sickle cell disease experience chronic anemia, with 
varying degrees of severity.1  The life-long anemia is likely caused by he molysis,1 or the 
destruction of red blood cells.30 
            3.1.2.2 Spleen 
As normal blood enters the spleen through the splenic artery, it must pass through progressively 
smaller arterial vessels,30 undergoing mechanical stress and physical remodeling.1  In sickle cell 
disease, the red blood cells are more rigid and are unable to pass through the splenic sinus gaps,1 
resulting in increased destruction of red blood cells.1,30  If there is vaso-occlusion or splenic 
congestion that continues without resolving on its own, the spleen may become enlarged.1 
Individuals with sickle cell disease may experience splenic involvement, which may be 
characterized by the following: minimal change; splenomegaly; asplenia or hyposplenis; splenic 
sequestration crisis; and hypersplenism.1  Some individuals may not experience any signs or 
symptoms of an affected spleen, until they are exposed to high altitudes.  At this time, they may 
experience abdominal pain as a result of splenic infarction.1 
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Splenomegaly is more commonly seen in children, particularly those under the age of 6 
years, compared to adults with sickle cell disease.1Splenic sequestration may occur in individuals 
with splenomegaly, in which the blood becomes trapped in the spleen.  Individuals may 
experience fever, pain and respiratory symptoms.  Splenic sequestration may present as splenic 
enlargement, which is often tender, a drop in hemoglobin concentration of at least 2 g/ dL, 
thrombocytopenia, and/or reticulocytosis.31Studies have suggested that infants who experience a 
splenic sequestration episode may experience a second event within 12 months of the initial 
event.32  Splenic sequestration can be life threatening if left untreated, even for a few hours.    
            3.1.2.3 Infection 
Infection is a major cause of morbidity and mortality in patients with sickle cell disease, with 
bacterial infection being the most common cause of death in infants and young c hildren with 
sickle cell disease.1  Table 2 includes bacteria and viruses that most frequently cause serious 
infection in patients with sickle cell disease.1  The most common organism causing infection is 
pneumococcus and individuals under the age of 3 years are particularly at an increased risk of 
infection.  Due to this knowledge, the initiation of prophylactic penicillin, which pneumococcus 
is extremely sensitive to,1 in the first few months of life has been an effective and inexpensive 
form of treatment in individuals with sickle cell disease.   
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Table 2:  Bacteria and viruses that most frequently cause serious infection in patients with sickle cell 
disease1 
Microorganism  Type of Infection Comments  
Streptococcus pneumonia Septicemia Common despite prophylactic penicillin and 
pneumococcal vaccine 
Meningitis Less frequent than in years past 
Pneumonia Rarely documented except in infants and 
young children  
Septic arthritis Uncommon 
Hemophilus influenza, type b Septicemia, meningitis, pneumonia Much less common in recent years because 
of immunization with conjugate vaccine  
Salmonella species  Osteomyelitis, septicemia  Most common cause of bone and joint 
infection  
Escherichia coli  and other Gram-negative 
enteric pathogens  
Septicemia, urinary tract infection, 
osteomyelitis  
Focus sometimes inapparent 
Staphylococcus aureus Osteomyelitis  Uncommon 
Mycoplasma pneumonia  Pneumonia  Pleural effusions; multilobe involvement  
Chlamydia pneumonia  Pneumonia  
Parvovirus B19 Bone Marrow suppression (aplastic crisis) High fever common; rash and other organ 
involvement infrequent 
Hepatitis viruses (A, B, and C) Hepatitis  Marked hyperbilirubinemia 
            3.1.2.4 Growth and Development 
Infants with sickle cell disease are born within normal weight and length and their early growth 
appears to be normal as well.  As time progresses, the mean height and weight of individuals 
with sickle cell disease may drop below the 50
th
 percentile, particularly by the age of 2 years.  As 
children age, these growth deficits may become progressively more pronounced.
1
  Studies have 
shown that an individuals weight is more severely affected than height.
1,34
 
Individuals with sickle cell disease may also experience delays in sexual maturation.  
Females with sickle cell disease may experience a delay in the onset of menarche and the 
progression through Tanner stages of development.
1
  Males with sickle cell disease also 
experience delays in the progression through Tanner stages of development along with lower 
levels of testosterone, dihydrotestosterone, and androsteneion.
1
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            3.1.2.5 Neurological 
Studies show that 24% of individuals with sickle cell disease may experience a f orm of 
neurologic injury, with the major cause being associated with cerebrovascular disease.1  
Cerebrovascular disease may present as cerebral infarction or intracranial hemorrhage.  Young 
individuals with sickle cell disease are predisposed to stroke, and may experience a st roke 
following a pain crisis, infection, or other systemic illness.1  Although it may occur following 
these events, it is uncertain if these events are causative.  A form of stroke, known as ischemic 
stroke, is common in individuals with sickle cell disease and is caused by oxygen deprivation 
due to occlusion of blood vessels.1  I ndividuals who experience stroke typically make a good 
recovery of motor function yet, they may experience some cognitive deficits.1  An intracranial 
hemorrhage may destroy the brain as a result of direct trauma from arterial jets of blood, by 
delayed vasospasm causing arterial narrowing that can produce infarction, or by compression of 
normal tissue by mass effect.1 
Individuals with sickle cell disease may also experience other neurological injury, such as 
hearing loss, neuropathy, or cognitive dysfunction.  The cause of hearing loss is currently 
unknown, but may be a result of vascular compromise.1  Neuropathy may present as m ental 
nerve lesions causing numbness of the chin.1 
            3.1.2.6 Bone 
Individuals with sickle cell disease may experience bone and joint concerns, primarily due to a 
limited blood supply to the region.  B one complications may include bone infarction or 
osteomyelitis.1  Bone infarctions may occur in the long bones, leading to swelling and tenderness 
localized to the area.1  An example of this is dactylitis in early childhood, also known as the 
“hand-foot syndrome.”1  This syndrome is typically the first manifestation seen in infants with 
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sickle cell disease between the ages of six months and two years.1  These infants experience 
infarctions in the small long bones of the hands and feet, causing painful swelling of the hands 
and feet.1 
Some individuals with sickle cell disease may also present with osteomyelitis, an acute or 
chronic bone infection, most often caused by salmonellae.1  Bone infarctions and osteomyelitis 
may present similar and may be difficult to distinguish.1The onset of symptoms may assist with 
distinguishing, with infarctions beginning more acutely, while osteomyelitis may have a more 
prolonged onset.1 
            3.1.2.7 Pulmonary 
Individuals with sickle cell disease may present with a variety of chronic manifestations 
including restrictive and obstructive lung disease, hypoxemia, pulmonary hypertension, airway 
hyperreactivity, asthma, or sleep-related upper airway obstruction.35-37  Pulmonary complications 
may present as acute or chronic disorders.1 
The most common acute complication seen in individuals with sickle cell disease is acute 
chest syndrome, occurring in 15-43% of affected individuals.1  Acute chest syndrome occurs as a 
result of vascular occlusion or infection in the lungs.30  I ndividuals experiencing acute chest 
syndrome may experience chest pain, tachypnea, fever, rales and rhonchi, leukocytosis, or lobar 
consolidations.30 
            3.1.2.8 Renal 
In a typical kidney, an average of 4-8% of the body’s total oxygen is consumed to assist in the 
elevated metabolic activity performed by the tubules.1 One of the main renal complications seen 
in individuals with sickle cell disease is occlusion of the vasarecta capillaries in the renal 
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medulla,38 leading to a change in the delivery of oxygen to the kidney,1 which in turn leads to 
ischemic damage.1 
The most prevalent clinical manifestation of sickle cell renal disease is hematuria, which 
may occur as a co nsequence of papillary infarcts or necrosis.1,38  Hematuria has been seen in 
individuals with sickle cell disease, along with those with sickle cell trait.1  B leeding occurs 
primarily from the left kidney; however, it has occurred bilaterally in rare cases.1  Hematuria 
may be painless38 and can be diagnosed by the use of radiography.1 
Additional clinical manifestations seen in individuals with sickle cell disease include 
proteinuria and hypertension; renal infarction, papillary necrosis, and renal colic; nephrogenic 
diabetes insipidus that can lead to polyuria; focal segmental glomerulosclerosis that can lead to 
end-stage renal disease; and renal medullary carcinoma.38  End-stage renal disease may occur in 
4-18% of individuals with sickle cell disease,1 Dialysis seems to be well tolerated by these 
individuals and there have been an increasing number of patients over the years that are now 
being treated with renal transplantation.38 
            3.1.2.9 Ophthalmologic 
Individuals with sickle cell disease may experience ophthalmologic complications as a result of 
erythrocyte sickling, which can occur in any microvascular bed of the eye.1  Depending on the 
tissue that is involved and the location of the vaso-occlusion, an individual’s vision may or may 
not be affected.1  I n individuals who experience ophthalmologic complications, primarily the 
retina is affected,39,40 and they may experience proliferative retinopathy, retinal artery occlusion, 
or retinal detachment and hemorrhage.39,40 
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            3.1.3 Management 
The main objectives in the management of patients with sickle cell disease include prevention 
and treatment of complications of sickle cell disease.41  In an attempt to prevent the 
complications associated with sickle cell disease, the aim is to establish routine follow-up with a 
comprehensive team, which includes a clinician and a variety of multidisciplinary interventions, 
such as pharmacological, behavioral, psychological, and physical interventions.42-44  During 
routine visits, clinicians should establish steady state values for an individual, to allow for 
comparison during episodes of complication.  Laboratory values such as hemoglobin, white 
blood count, and pulse oximetryreadings can be informative.42,43  R outine evaluations should 
also include neurology, ophthalmology, cardiology, pulmonary, psychological/behavioral, and a 
general physical evaluation.45-49 
Children with sickle cell disease should undergo a transcranial Doppler in order to 
evaluate the cerebral blood flow.  T his procedure should be performed at least every 12-24 
months beginning at the age of two until a child reaches the age of 16.45  TranscranialDopplers 
are not required for individuals over the age of 16 years.45  Once a child with sickle cell disease 
becomes of school age, they should undergo retinal evaluation on a routine basis.  Starting at the 
age of 15, individuals with sickle cell disease should undergo an echocardiogram at least every 
other year.46  T his recommendation is based on findings indicating an association of elevated 
tricuspid regurgitant jet velocity evident on echocardiograms with increased mortality.46 
Pulmonary complications are associated with sickle cell disease; therefore, baseline pulmonary 
function studies should be performed on individuals with sickle cell disease at least every two 
years.   
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Sickle cell disease, being a chronic disease, can have major psychological complications.  
Due to the clinical manifestations associated with the disease, such as pain episodes and the 
implication they have on an individual’s life, depression can be a significant component of the 
disease.  P ain episodes can also affect everyday life activities, such as school and work; 
therefore, assistance in these areas may be required.  Family planning and birth control 
counseling may also be discussed in families with a h istory of sickle cell disease.  A  routine 
physical exam is recommended for assessment of bone health by calcium intake, vitamin D 
status, and bone density at 12 years of age.48  A chemistry panel and urinalysis should also be 
performed twice a year, in an attempt to monitor renal disease, proteinuria, and organ 
dysfunction.49 
            3.1.3.1 Management of Infection 
Bacterial infection is the most common cause of death in infants and young children with sickle 
cell disease and a significant cause of morbidity in older patients.1  The highest rates of infection 
appear to affect younger patients, particularly those under the age of 3.1  Since we are aware of 
this risk of infection, and with our ability to diagnosis sickle cell disease by newborn screen in 
the first few weeks of an infant’s life, the administration of penicillin V is initiated within three 
months of birth.50,51  A  twice daily oral dose of 125 m g is administrated until the age of 2-3 
years, at which time the dose is increased to 250 mg twice daily until the age of 5.50,51  After the 
age of 5, parents may elect to continue or stop treatment.  This option is available to parents due 
to the uncertainty of the benefits and risks of continuing treatment with penicillin V after this 
age.51  Regardless of the decision a parent makes, monitoring for fever should continue.52 
Children with sickle cell disease should also receive routine vaccinations, including 
immunization against Streptococcus pneumonia, Haemophilus influenza type B, hepatitis B 
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virus, and influenza.53-56  If a ch ild with sickle cell disease encounters a fever, they should 
undergo an evaluation that includes a physical examination, a complete blood count, blood and 
urine cultures, and a chest x-ray.  If meningitis is suspected, a lumbar puncture should also be 
performed.   
            3.1.3.2 Splenic Sequestration 
Splenic sequestration may occur in individuals with sickle cell disease, presenting as splenic 
enlargement, which is often tender, a drop in hemoglobin concentration of at least 2 g/ dL, 
thrombocytopenia, and/or reticulocytosis.31  The primary concern surrounding splenic 
sequestration is hypovolemic shock.33  This becomes a concern as a result of a disproportionate 
amount of intravascular blood volume becoming sequestered in the spleen due to ensnared red 
and white blood cells.31 
Management is typically initiated following an initial event.  Patients should be educated 
about self-palpation of the spleen and instructions on w hat to do in the event of an enlarging 
spleen.31-33  Following an event, individuals with sickle cell disease may contemplate removing 
the spleen, once they evaluate the risks and benefits of the procedure.31-33  Regular blood 
transfusion therapy may also be considered in an attempt to prevent subsequent episodes of acute 
splenic episodes; however, the exact benefits of this type of therapy have yet to be proven.31-33 
            3.1.3.3 Pain Management 
Acute, painful episodes are the most common cause for sickle cell disease patients to seek 
medical attention.57  The definition for an acute, painful episode may vary depending on t he 
source.  The Cooperative Study of Sickle Cell Disease (CSSCD) defined a pain episode as pain 
related to sickle cell disease in the extremities, back, abdomen, chest or head lasting at least two 
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hours and leading to a clinic visit or hospitalization.57  S tudies have shown that the annual 
incidence rate of pain episodes does increase with age; however, these rates may be greatly 
underestimated due to the fact that many adults who experience an acute, painful episode do not 
seek medical attention.58  Instead of seeking medical attention, many patients attempt to manage 
their pain at home.  Studies have shown that many adults with sickle cell disease experience pain 
on almost a daily basis58 and manage this pain at home until it exceeds their ability to maintain 
with oral opioids.58 
Home management of pain associated with sickle cell disease is similar to the World 
Health Organization (WHO) guidelines for the treatment of cancer-related pain.59  These 
guidelines use a stepwise approach, by which the therapy is increased as the severity of the pain 
increases.59  Patients with sickle cell disease are recommended to work along with their clinician 
and multidisciplinary team to create a standard treatment plan for their management at home.   
Once a patient with sickle cell disease seeks medical attention, the emergency department 
should initiate prompt treatment according to the American Pain Society (APS).59,60  APS 
outlines steps to ensure proper and effective treatment of pain once a sickle cell patient is present 
in an emergency department.  A patient’s team, to ensure effective treatment and management of 
pain for that particular patient, may also compose individual pain management plans.   
Much effort has been put forth in an attempt to discover therapies that treat severely 
affected sickle cell disease patients, particularly when it comes to pain management.  
Hydroxyurea is a therapy used for the overall management of sickle cell disease.  Hydroxyurea 
was FDA-approved in 1998 f or the use of severely affected adults with sickle cell disease.61  
Hydroxyurea therapy is believed to reduce hemolysis and vaso-occlusion as a result of the 
prevention of intracellular sickling.61  The underlying concept of Hydroxyurea is that it increases 
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the percentage of fetal hemoglobin.61  Clinical observations have suggested that increased fetal 
hemoglobin concentrations have beneficial effects in sickle cell disease,61 which may be 
attributed to fetal hemoglobin lacking β-chains.62  The process of sickling of the red blood cells 
is triggered by deoxygenated hemoglobin S, which undergo polymerization and transform into 
rigid rod-like polymers.62  The lack of β-chains inhibits the polymerization of hemoglobin S, 
decreasing the occurrence of sickling events.   
A controlled trial of the efficacy of Hydroxyurea in patients with sickle cell anemia was 
performed by Char ache et al,62 which involved 148 males and 151 females across 21 clinics, of 
which 152 patients were assigned to Hydroxyurea treatment.62  This study demonstrated that the 
treatment with Hydroxyurea caused a 44% reduction in the median annual rate of painful 
episodes, along with reducing the frequency of chest syndrome and the number of transfusions.62  
Hydroxyurea has been shown to be effective within two months of beginning treatment, with 
noticeable differences by four months of use.62 
The risks associated with the use of Hydroxyurea is still unclear, particularly use during 
pregnancy.62,63  There is a concern for the long-term use of Hydroxyurea and the risk of cancer, 
birth defects and leg ulcerations.63  Given the fact that Hydroxyurea blocks the synthesis of DNA 
by inhibiting ribonucleotide reductase, similar to other antieoplastic agents, the trepidation is that 
Hydroxyurea may be carcinogenic or leukemogenic.62  Sickle cell patients and clinicians must 
weight out the benefits of Hydroxyurea treatment with the uncertain safety of the long-term 
Hydroxyurea therapy.62 
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            3.1.3.4 Transfusion Therapy 
Transfusion of normal blood in patients with sickle cell disease allows for the addition of normal 
red blood cells, lowering the percentage of red blood cells containing Hb S.64  Exchange 
transfusion is the process of theoretically replacing Hb S with HbA.64  T his process involves 
transfusing normal blood in, while removing other blood.8,64  E xchange transfusion is more 
commonly utilized in individuals with initially high concentrations of Hb S.8  In these 
individuals, a rapid reduction in the Hb S percentage is required, which is ideally achieved 
through the process of exchange transfusion.8  The indications for blood transfusion in sickle cell 
disease can be found in Table 3.8 
The benefits of transfusion include the management of acute complications associated 
with sickle cell disease.  T hese may include acute stroke, acute chest syndrome, acute multi-
organ failure, and acute symptomatic anemia.  Other complications associated with sickle cell 
disease, such as splenic sequestration, may also be managed through transfusion therapy.  Aside 
from the evident benefits associated with transfusions, much controversy surrounds chronic 
transfusion therapy.  R isks associated with chronic transfusion therapy include iron overload, 
transfusion reactions, viral infection, and alloimmunization.8Just as in any type of therapy that 
carries a risk, the potential benefits need to be weighted against the potential risks, when making 
management decisions.  
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Table 3: Indications for blood transfusion in sickle-cell disease8 
Indications for acute transfusions 
Acute exacerbation of anemia 
Typically caused by Parvovirus B19 infection, splenic or hepatic sequestration, or severe vaso-occlusion; simple 
transfusion is necessary to increase hemoglobin concentrations to 80–90 g/L 
Acute chest syndrome 
Early simple top-up transfusion is beneficial, with exchange transfusion to reduce Hobs to less than 30% if 
deterioration of clinical condition occurs 
Stroke or acute neurological deficit 
Urgent transfusion to increase hemoglobin concentrations to 100 g/L, and reduce Hobs to less than 30%, which 
typically requires exchange transfusion 
Multiorgan failure 
HbS to less than 30% with hemoglobin concentration of 100 g/L 
Preoperative management 
Target HbS of less than 30% before major surgery (cardiothoracic, neurosurgery), typically requiring exchange 
transfusion; medium-risk or low-risk surgery might need simple transfusion to increase hemoglobin 
concentration to 100 g/L 
 
Indications for regular, long-term transfusions 
Primary and secondary stroke prevention 
Regular transfusions, either simple or exchange, to keep HbS less than 30% 
Recurrent acute chest syndrome not helped by hydroxycarbamide 
Regular transfusions, either simple or exchange, to keep HbS less than 30% 
Progressive organ failure 
Including hepatic, renal, cardiac, and pulmonary failure; little evidence-based practice and transfusion strategies vary 
widely 
Other indications 
Recurrent splenic sequestration, complicated pregnancy 
Controversial indications 
Frequent acute pain, chronic pain, avascular joint necrosis, leg ulcers, priapism 
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3.2 SICKLE CELL TRAIT 
In the United States, the prevalence of SCT among African Americans is about 8%, or 1 in 12 
African Americans.3,9,65,66,67  Sickle cell trait, or sickle cell carriers, are characterized by the 
presence of both Hb A and Hb S, giving them the genotype Hb AS.4,68  The amount of Hb S 
present can vary among individuals with sickle cell trait.  The amount tends to be less than 50%,4 
with the majority of the red cells containing between 20-45% Hb S.4  As previously mentioned, 
when oxygen levels are decreased, polymerization of Hb S can occur, leading to a sickling 
process.4,68  The amount of sickling that occurs in individuals with sickle cell trait depends on a 
number of factors, including the amount of Hb S present, along with the degree of hypoxia and 
other factors that attribute to a sickling event.4 
            3.2.1 Health Implications 
Individuals with sickle cell trait are believed to have a benign condition4and are generally 
asymptomatic with a normal life span.69  Studies have demonstrated that individuals with sickle 
cell trait may actually be at a slightly increased risk for developing sickle hemoglobin-related 
pathology.4,65,69  The potential complications that are associated with sickle cell trait include 
renal disease,70-73 thrombosis,74-76 rhabdomyolysis, and the risk for sudden death associated with 
exercise.77,78 
In individuals with sickle cell trait, episodes of hematuria can be common, along with 
impaired urinary concentrating ability.70,71Urinary infections can be seen in individuals with 
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sickle cell trait, more frequently occurring in women with sickle cell trait.4  The occurrence of 
these events is closely related to the concentration of Hb S present.72,73Urinary tract infections or 
sepsis may be a symptom seen in individuals with papillary necrosis, which is the most frequent 
cause of gross hematuria in individuals with sickle cell trait.74   
Cases of splenic infarction have occurred at high altitudes in individuals with sickle cell 
trait.4,75,80  Splenic infarction may present as severe abdominal pain, localized to the left upper 
quadrant.80  The spleen may feel tender and enlarged, and individuals may experience nausea and 
vomiting.80 
Rhabdomyolysis has been reported in individuals with sickle cell trait, particularly 
following extreme exertion.4  It is believed that extreme physical exertion can lead to damage of 
the muscle cells (Harrelson).  Once muscle cells become damaged, myoglobin and other 
enzymes are released into the blood.  Once myoglobin reaches a certain level in the blood, it is 
released into the urine, darkening its color, which is known as myoglobinuria.  This can then 
progress to renal failure.81  Rhabdomyolysis is also defined by increased plasma creatinine 
kinase (CK) levels, which may be more than five times normal levels.82 
Due to these findings, it has been demonstrated that prolonged physical and extreme 
exertion has been the most significant trigger for serious risks associated with sickle cell 
trait.4,67,80 
             3.2.2 Sickle Cell Trait and Exercise 
There has been increasing awareness regarding the association of sickle cell trait and sudden 
death during exercise.  It is believed that during periods of extreme physical activity, athletes 
with sickle cell trait have an increased risk for sudden death, although it is  quite rare.  It is  
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hypothesized that if an athlete has sickle cell trait, intense exercise can produce physiological 
changes to Hb S, leading to polymerization of Hb S,80 which in turn creates a sickling event; an 
event referred to as exertional sickling.  Over a ten year period, of 136 sudden, non-traumatic 
sports deaths in high school and college athletes, seven (5%) were thought to be due to exertional 
sickling.   
The major concerns surrounding an athlete with sickle cell trait include splenic infarction, 
gross hematuria, and grave exertional rhabdomyolysis.65  Given these complications, the most 
important potential complication of sickle cell trait with exercise is unexpected death.80 
            3.2.2.1 Military 
The military first tied sickle cell trait to sudden death during recruit basic training.65  The first 
cases identifying an association between sickle cell trait and sudden death involved four U.S. 
Army recruits at Fort Bliss, TX.67  These four recruits died during or immediately after strenuous 
exercise during basic training between March of 1968 and February of 1969.67  Based on 
autopsy, it was concluded that the recruits died of diffuse microvascular obstruction from sickled 
erythrocytes, or “sickle crisis.”67  These cases at Fort Bliss demonstrated a strong association of 
sudden unexplained death with sickle cell trait.80 
One of the largest military studies was performed by Kark, between January 1, 1977 and 
December 31, 1981.83  This study enlisted 2.1 million recruits, aged 17-34 years old, who entered 
basic training during the length of the study.83  Military service records were used to determine 
which deaths had occurred among recruits during basic training and autopsy files, along with 
other documentation, was utilized to record the deaths.83  B etween 1977 and 1981, 80 deaths 
occurred, of which, 62 were considered natural deaths occurring during military basic training;83  
35 of the sudden deaths were closely associated with exercise; 13 of these recruits were reported 
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to have hemoglobin AS, all were African American, and all had sudden deaths related to 
exercise.   
The majority of this data suggests an association between sickle cell trait and exercise-
induced sudden death; however, many experts question the validity due to the difficulty of 
differentiating between postmortem and antemortem sickling.  Autopsy reports performed on the 
recruits indicated the presence of sickled cells in tissues,80 although, postmortem sickling is well 
documented in sickle cell trait and can be expected with death from any cause.67  Even though a 
causal relationship is plausible given the cases of sudden death among recruits, no direct 
evidence links these deaths to microvascular obstruction by rigid erythrocytes.67,80 
            3.2.2.2 Athletes 
In addition to cases present in military setting there have been a number of cases involving 
sudden death among athletes, which have been associated with sickle cell trait.  A report by Van 
Camp et al in 1995 i llustrated non-traumatic sports-related deaths of high school and college 
athletes over a ten-year period.84  During the duration of this study, 7 deaths with exertional 
rhabdomyolysis, associated with sickle cell trait, were reported.84 
            3.2.2.3 Guidelines 
Although the majority of fatalities associated with sickle cell trait occurred without any 
knowledge of proceeding exercise-related illness, if any warning events occur, they should be 
taken seriously.80  Individuals with sickle cell trait may present with high levels of CK following 
exercise, exhibit recurring episodes of heat exhaustion, or a serious episode of rhabdomyolysis.80  
Following the occurrence of any of these warning events, it is suggested that an individual 
refrain from demanding conditioning or competitive sports, as a precaution.80 
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The major cause of mortality associated with sickle cell trait and exercise appears to be 
exertional heat illness.
80
  Therefore, a number of precautions are recommended, in an attempt to 
avoid exertional heat illness.  A major contributor to exertional heat illness is dehydration.  
Adequate hydration is essential at all times surround exercise.  This includes staying hydrated 
before, during, and after exercise.
80
  Adequate hydration may be more difficult, particularly for 
individuals with sickle cell trait due to a limited capacity for them to concentrate urine, leading 
to a decreased ability to compensate for negative water balance during exercise.
80 
 
A sickling event is more often confused with heat cramping, heat exhaustion, or heat 
stroke.
85
 The most telling symptom of a sickling event is increasing pain and weakness in the 
working muscles, especially the legs, buttocks, and/or lower back.
85
  Notable differences 
between heat cramping and a sickling event can be found in Table 4.
85 
 
 
 Heat cramping often has a prodrome. Hours or minutes before the athlete suffers heat cramping, 
he may see or feel twitching or twinges in tired muscles, those destined to cramp. The athlete 
who knows heat cramps will tell you, “They are about to come on.” In contrast, sickling has no 
prodrome.  
 The pain is different. Heat-cramping pain is an excruciating pain of sustained, full contraction of 
muscles, a “lock-up.” Sickling pain is milder, neither the unbearable pain of a heat-cramp lock-
up nor the “burning” pain in the thighs as at the end of a middle-distance race. Sickling pain is an 
ischemic pain from trying to use muscles robbed of blood supply – it is like the pain of 
intermittent claudication when leg arteries are narrowed by atherosclerosis.  
 What stops the athlete is different. With heat cramping, athletes “hobble to a halt” – the fully 
contracted muscles no longer work. With sickling, athletes “slump to a stop” – the legs become 
“weak and wobbly” and no longer hold them up.  
 The physical findings are different. In major heat cramping, one can see and feel large, rock-hard 
muscles in full contraction, and the athlete often is writhing and yelling in pain. With sickling, 
the exhausted player lies fairly still and complains little, except to say that he feels bad and his 
legs hurt and are weak. The muscles look and feel normal.  
 The response is different. After 10-15 minutes sitting in a cold tub, drinking fluids, and getting 
supplemental oxygen by facemask, the athlete with mild sickling “feels fine.” This is likely 
because many sickle cells have reverted to normal as they regained oxygen. In contrast, major 
heat cramping often takes an hour or two to resolve, even in a player resting in the training room, 
being treated with stretching, massage, and intravenous fluids.  
 
Table 4: Notable Differences Between Heat Cramping and Sickling Event85 
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Individuals participating in conditioning activities should allow for gradual buildup.  
They should begin at an easily tolerated level and work up to near their maximal effort.80  If an 
individual feels ill or is experiencing distressing symptoms, they should limit the amount of 
exercise they participate in.80  This is true, particularly for the two weeks following any viral 
syndrome, respiratory infection, chest symptoms or syncope.80  If an individual is participating in 
any activities occurring in hot weather conditions, the appropriate adjustment should follow for 
clothing, work-rest cycles, sun exposure, and an individuals maximum effort put forth.80 
These precautions may help minimize the risk of severe exertional heat illness; 
unfortunately, they cannot eliminate the risk of unexpected deaths.80  Even though individuals 
with sickle cell trait may be at a slightly increased risk for these events to occur, these guidelines 
are important measures that should be followed by e veryone who engages in demanding 
exercise.80 
The NCAA has also issued precautions for their athletes with sickle cell trait to follow, 
which are illustrated in Table 5.86  If, after following these precautions, a sickling collapse does 
occur, it should be treated as an emergency and the proper actions should be taken into 
consideration (Table 6).85 
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Table 5: NCAA precautions for student athletes with sickle cell trait86 
 
 Set their own pace 
 Engage in slow and gradual preseason conditioning regimen to be prepared for 
sports-specific performance testing and the rigors of competitive intercollegiate 
athletes 
 Build up their intensity slowly while training 
 Use adequate rest and recovery between repetitions, especially during “gassers” 
and intense station or “mat” drills 
 Not be urged to perform all-out exertion of any kind beyond two to three minutes 
without a breather 
 Be excused from performance tests such as serial sprints or timed mile runs, 
especially if these are not normal sport activities  
 Stop activity immediately upon struggling or experiencing symptoms such as 
muscle pain, abnormal weakness, undue fatigue or breathlessness 
 Stay well hydrated at all times, especially in hot and humid conditions 
 Maintain proper asthma management  
 Refrain from extreme exercise during acute illness, if feeling ill, or while 
experiencing a fever 
 Access supplemental oxygen at altitude as needed 
 Seek prompt medical care when experiencing unusual distress 
 
 
Table 6: Treating sickling collapse as a Medical Emergency85 
 
 Check vital signs  
 
 Give supplemental oxygen by face mask 
 
 Cool the athlete, if necessary 
 
 Failing immediate improvement, call 911, attach an AED, and start an 
intravenous line 
 
 Get the athlete to the hospital quickly 
 
 Tell the doctors to expect explosive rhabdomyolysis and its grave 
metabolic complications  
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3.3 SICKLE CELL TRAIT TESTING 
            3.3.1 Methods 
The diagnosis of sickle cell disorders is a fairly simple process.  The diagnosis process can be 
divided into three main categories: tests for sickle hemoglobin, methods for identifying 
genotype, and methods for distinguishing sub-groups of the genotypes.4 
Two tests exist that are used to detect sickle hemoglobin.  The sickle test was the first test 
developed to detect sickle hemoglobin, through the process of identifying morphological changes 
in the red blood cells once they becomedeoxygenated.4  T he method created by Daland and 
Castle (1948) is the standard technique used today, in which a drop of 2% solution of sodium 
metabisulphite is mixed with one drop of blood on a  microscope side.  The sample is then 
covered with a coverslip and sealed, in order to prevent oxygen from reaching the sample.  I f 
sickle hemoglobin is present, sickling usually occurs within one hour and can be visible under a 
microscope.4,87 
The second test, solubility test, is a slightly newer method.  Goldberg (1958) utilized the 
knowledge of the relatively insolubility of deoxygenated sickle hemoglobin in solutions of high 
molarity to create this method.4,88  When combined with buffers, lysing, and reducing agents, 
samples containing sickle hemoglobin become cloudy, while samples lacking sickle hemoglobin 
remain clear.88  Both tests available for sickle hemoglobin provide information on the presence 
or absence of sickle hemoglobin; however, these results do not distinguish between different 
genotypes that account for sickle cell disorders.   
In order to differentiate between the genotypes of sickle cell disorders, hemoglobin 
electrophoresis is the technique utilized.4  Hemoglobin electrophoresis is the major technique 
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used for the diagnosis of sickle cell disorders in the neonatal and postnatal periods of life.4 
Hemoglobin electrophoresis at alkaline pH is a method commonly used, since some variant 
hemoglobins have different charges from Hb A at this particular pH.1  Hb S migrates more 
slowly towards the anode than does Hb A, while Hb C migrates slower than Hb S.1  A limitation 
of this method is the difficulty to differentiate between abnormal hemoglobins of the same 
charge.4  In order to distinguish between these abnormal hemoglobins, DNA analysis would need 
to be performed.  
            3.3.2 Military 
Prior to 1982, individuals with sickle cell trait were restricted in certain areas of the United 
States military.  These restrictions refrained individuals with sickle cell trait from entering into 
flight training, aircrew duties, and the U.S. Air Force Academy.89  At this time, sickle crises were 
believed to be the cause of the rare occurrence of unexpected death among individuals with 
sickle cell trait. Therefore, individuals with sickle cell trait were restricted from precipitating 
conditions, such as high altitude.   
By 1985, the Secretary of Defense stated:  
“all military occupational restrictions on sickle cell trait (SCT) 
bearers are to be removed effective immediately…. No sickle cell 
trait bearer will be subjected to any additional screening beyond 
that required of all candidates for that occupation.”89 
 
Since this time, each branch of the U.S. military has developed their own policy regarding 
screening for sickle cell.67  In 1996, the Army ceased screening for the sickle gene.67  The 
Marines currently screen all individuals for the sickle gene; however, the Marines impose no 
restrictions on individuals with sickle cell trait.67  The Air Force screens everyone for the sickle 
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gene.  Individuals who are identified as having sickle cell trait are offered the option to decline 
service.67  The Navy also screens all recruits for the sickle gene, but they distinguish recruits 
with sickle cell trait from others with a neck tag and a red belt during strenuous exercise drills.67 
             3.3.3 Athletes 
Over the years, there has been a number of reported sudden death among athletes, which have 
been associated with sickle cell trait.  In 2006, a 19-year-old freshman attending Rice University 
died following a football practice.  His death was attributed to acute exertional rhabdomyolysis 
associated with sickle cell trait.69  In an attempt to bring attention to the event and in the hope of 
preventing other deaths, the family of the football player filed a lawsuit against the National 
Collegiate Athletic Association (NCAA) and Rice University.69 
In 2007,  the National Athletic Trainer’s Association and the College of American 
Pathologists recommended that colleges and universities consider screening athletes for sickle 
cell carrier status in an effort to save lives.69  Following the settlement of the lawsuit against the 
NCAA and Rice University in 2009, the National Athletic Trainers Association (NATA) and the 
College of American Pathologists (CAP) recommended that all athletes were aware of their 
sickle cell trait status.90  The recommendation was that if an athlete’s sickle cell trait status was 
unknown, the NCAA recommended that athletic departments confirm sickle cell trait status 
during the Medical Examination period.90 
Most recently, on April 13, 2010, the legislative council for Division I of the NCAA 
approved mandatory testing for sickle cell carrier status (sickle cell trait) for all student athletes 
participating in Division I sports69, which went into effect August 1, 2010.  The NCAA 2010-
2011 Sports Medicine Handbook states that all student-athletes new to their campus are required 
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to complete a sickle cell solubility test, show results of a prior test, or sign a written release 
declining the test.91 
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4.0  PROGRAM DESIGN 
4.1 COLLABORATION WITH UNIVERSITIES 
Following the NCAA recommendation in 2009, the University of Pittsburgh Department of 
Athletics contacted the Children’s Sickle Cell Program at Children’s Hospital of Pittsburgh 
regarding testing its athletes for sickle cell trait.  At that time, the Children’s Sickle Cell Program 
offered testing services, along with genetic counseling, to the University of Pittsburgh Athletic 
Department.  C ontact was created through the athletic training coordinator to establish the 
coordination of testing for the student-athletes.  Contact with the athletic training coordinator 
was continued throughout the year, and upon the revised recommendations by t he NCAA in 
April of 2010, a modified plan to offer testing services and genetic counseling was established at 
that time.  Seven dates were established, between June and September 2010, at which time the 
annual physicals were to take place.  Genetic counseling and testing occurred during this time.  
Three additional dates were eventually arranged, at which time student athletes were brought in 
for the sole purpose of receiving genetic counseling and testing.   
 The previous year, the University of Pittsburgh offered testing on a voluntary basis.  
Following the revised recommendations established in 2010, testing remained voluntary; 
however, if a student athlete declined testing, they were required to sign a waiver, which was 
provided by the University of Pittsburgh.  Additional changes from the previous year included 
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adjustments to the payment of the testing.  Instead of the University of Pittsburgh covering the 
cost of testing, the testing was billed through each student athletes’ personal insurance plan.  If a 
student athlete did not have insurance, they were defaulted to the insurance provided by the 
University of Pittsburgh.  Our program provided our staff’s time at no cost and was able to offer 
the test at a research price of $12.50 per test.   
 In lieu of the revised recommendation mandating testing of all Division I student athletes, 
our program attempted to extend our services to other Division I A thletic Departments in the 
Pittsburgh area.  Contact was established with Duquesne University Department of Athletics 
Director of Sports Medicine.  A similar plan as that initiated at the University of Pittsburgh was 
established at Duquesne University.  Duquesne University elected to mandate testing for all of 
their incoming student athletes.  They did not provide their student athletes with the option opt 
out of testing by signing a waiver.  Five dates were established, at which the annual physicals 
were to take place.  Genetic counseling and testing occurred during this time.   
4.2 EDUCATION OF STAFF 
In 2009, following the testing process that was provided, educational material was offered to the 
coaching, training and athletic staff at the University of Pittsburgh, through a PowerPoint 
presentation (Appendix D).  This presentation provided education regarding sickle cell disease, 
sickle cell trait, and the NCAA’s recommendations regarding sickle cell trait.  The staff was also 
provided with prevention measures they could take to ensure the safety of all athletes.  
With the addition of Duquesne University in 2010, our program met with members of the 
coaching, training, and athletic staff at Duquesne University to provide them with the same 
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educational material.  The presentation given to the staff at Duquesne University was previously 
created and presented by Amy Aloe.   
4.3 DATA COLLECTION 
           4.3.1 Participant Recruitment 
The student athletes included in this project are enrolled in the study at the University of 
Pittsburgh, IRB #PRO10050224.  The principle investigator is Dr. Lakshmanan Krishnamurti.   
For this project, student athletes from the University of Pittsburgh and Duquesne 
University were asked if they would like to participate during their physicals, in which they were 
being tested for sickle cell trait.  Participation involved informed consent and the completion of a 
questionnaire.  T he addendum consent form for this project can be found in Appendix A.  
Participants were informed that their results and comments would remain confidential and all 
identifiers would be removed.  A questionnaire was presented to the participants prior to their 
counseling for the sickle cell trait testing.  Following the counseling session and blood draw, 
another questionnaire was presented.  Their participation was not linked to any of their medical 
or genetic information to the University of Pittsburgh.  There was no compensation for 
participation; 80 student athletes agreed to participate.   
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           4.3.2 Questionnaires 
A questionnaire was developed to obtain useful information from student athletes who were 
undergoing sickle cell trait genetic counseling and testing.  These documents can be found in 
Appendix B.  A pre-counseling questionnaire was presented to the student athletes prior to the 
genetic counseling session and a post-counseling questionnaire was presented to the student 
athletes following the genetic counseling session and the blood draw.   
The pre-counseling questionnaire was comprised of seven questions.  The pre-counseling 
questionnaire contained questions focusing on basic knowledge of sickle cell disease, sickle cell 
trait, and some differences between the two.  Ethnic backgrounds of the participants were also 
obtained from this questionnaire.   
The post-counseling questionnaire was similar to the pre-counseling questionnaire in that 
it repeated the basic knowledge questions of sickle cell disease, sickle cell trait, and some 
differences between the two.  In addition, the post-counseling questionnaire included questions 
regarding the patient’s experience with undergoing genetic counseling and genetic testing.   
           4.3.3 Counseling Education 
Every student athlete that was to undergo genetic testing received genetic counseling prior to the 
blood draw for genetic testing.  Material presented to the student athletes can be found in 
Appendix.  Sickle cell disease was first covered in the genetic counseling session.  B asic 
information on sickle cell disease and the effect on the red blood cells was discussed, followed 
by the inheritance pattern of sickle cell disease.  Sickle cell disease versus sickle cell trait was 
discussed and then the following information was broken down into two categories; information 
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regarding the impact of sickle cell trait on athletes and then the reproductive implications of an 
individual having sickle cell trait.   
For the impact of sickle cell trait on athletes, the athletes were informed that during 
periods of extreme physical activity, athletes with sickle cell trait have an increased risk for 
sudden death, although it is important to remember that this is quite rare.  It is believed that if an 
athlete with sickle cell trait participates in intense exercise, an event referred to as exertional 
sickling may occur.  During this event, rapid muscle break down may occur, which can be fatal.   
The athletes were informed that collapse due to exertional sickling typically occurs 
within the first 30 minutes of a practice.  Exertional sickling collapse can often be confused with 
heat exhaustion collapse, therefore, the athletes were presented with a sheet distinguishing these 
two events.  In order to prevent exertional sickling for occurring, the athletes were also provided 
with various forms of prevention.   
Athletes were counseled on  an individual basis or in a group of two athletes.  
Approximately five to ten minutes were spent on counseling and education with each athlete.    
            4.3.4 Testing 
All samples were collected on site at the University of Pittsburgh or Duquesne University’s 
athletic training facilities, respectively, immediately after the genetic counseling was completed.  
A registered nurse provided by our  program performed phlebotomy services.  Standard sterile 
procedures were performed and 2 m L of blood was collected in a sterile lavender-top EDTA 
collection vial (BD Vacutainer, 5.4 mg EDTA).  Following collection, the samples were 
transported back to Children’s Hospital of Pittsburgh diagnostic laboratories within 2-4 hours of 
collection.   
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Under the revised NCAA recommendations, student athletes were unable to practice with 
their team until their carrier status was known, or a waiver was signed.  To accommodate these 
time restraints, our laboratory offered to run all samples through a Hemoglobinopathy evaluation 
via electrophoresis, with the sole focus on hemoglobin S.  Upon the presence of hemoglobin S, 
that particular sample would then undergo standard Hemoglobinopathy evaluation via 
electrophoresis and whole red blood cell count.   
            4.3.5 Results and Disclosure 
In accordance with the time restrains, as previously mentioned, under the NCAA 
recommendations, the laboratory set up a  communication plan with our program to run the 
samples and report the results within 24 hour s of collection.  The respective athletic training 
department was contacted by telephone of any positive result.   
All results were then faxed to the respective athletic training department within 72 hours.  
Student athletes with a positive result were contacted by telephone within 24 hours of collection.  
Each result was then mailed to the corresponding student athlete with a letter interpreting the 
results.  All results were reported.   
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5.0  RESULTS 
5.1 TESTING 
Over the course of the testing process, 122 student athletes between the University of Pittsburgh 
and Duquesne University elected to have sickle cell trait testing.  We had a diverse group of 
athletes, across a variety of sports, including men’s and women’s soccer teams, track and field, 
cross country, and men’s and women’s basketball teams.  The population of student athletes 
varied in terms of gender and race/ethnicity, with the race/ethnicity documented in the 
questionnaires.   
All results were reported to the student athletes.  Of the 122 student athletes tested, one 
athlete was found to have sickle cell trait.  Follow up with this particular athlete was attempted 
without success.  This particular athlete ended up leaving the athletic program at the University 
of Pittsburgh for personal reasons.   
5.2 QUESTIONNAIRES 
Among the 122 student athletes tested, 80 participated in the questionnaires.  Data regarding the 
race/ethnicity of the participants was collected from the questionnaires.   Among those who 
participated, 57 ( 71%) were Caucasian, 16 ( 20%) were African American, and the remaining 
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athletes were of mixed or other ethnic backgrounds (Figure 3).  The pre-counseling and post-
counseling questionnaire contained the same five basic knowledge questions regarding sickle 
cell disease, sickle cell trait, and the differences between the two.  I took these five questions and 
analyzed the answers each student athlete provided for the pre-counseling questionnaire and then 
for the post-counseling questionnaire.   
 
 
 
 
 
 
 
For each questions, I first looked to see if the student athlete answered the question 
correctly on the pre-counseling questionnaire.  I  continued onto  the post-counseling 
questionnaire, and if they answered the question correctly on the post-counseling questionnaire 
as well, I considered that as “knowledge known.”  I f the student athlete did not answer the 
question correctly on the pre-counseling questionnaire, and when I continued on to the post-
counseling questionnaire, they answered the question correctly, I considered that as “knowledge 
learned.”  If there were any other scenarios, such as a student answering the question incorrectly 
on both the pre- and post-counseling questionnaire, or if they answered the question correctly on 
the pre-counseling questionnaire but incorrectly on the post-counseling questionnaire, then I 
considered it “still struggling after counseling.”  These steps were then repeated for the four 
remaining questions.  The totals from this analysis can be found in Figure 5.  
Figure 3: Ethnicity of Student Athletes 
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Figure 4: Results from Questionnaires 
 
Once each question was analyzed in such a fashion and the totals calculated, the data 
from each question was combined, to create a percentage for each level of knowledge: “knew,” 
“learned,” and “still struggling after counseling;” which is displayed as overall knowledge in 
Table 7.  
 
 
 
 
 
 
Table 7: Overall Knowledge of student athletes gained from the questionnaire 
Overall Knowledge 
Knowledge  
Percentage of Student Athletes 
Surveyed 
Knew 62% 
Learned  14% 
Still struggling after counseling 23% 
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After reviewing these results, a question in particular stood out as seeming confusing for 
the student athletes.  This question asked: “If a person with sickle cell trait could ever develop 
disease?”  Based on the result from that question in particular, 12 student athletes knew the 
correct answer, 9 student athletes learned the correct answer during the counseling session; 
however, 57 student athletes seemed to still struggle with this question after counseling.  The 
question was meant to indicate the development of sickle cell disease if an individual has sickle 
cell trait.  It may have been interpreted as developing symptoms associated with an exertional 
sickling event.  Due to the ambiguity of this particular question, it was excluded.  Once removed, 
the new totals were calculated as “Modified Knowledge” (Table 8).   
 
Table 8: Modified Knowledge of student athletes gained from the questionnaires 
Modified Knowledge 
Knowledge  
Percentage of Student Athletes 
Surveyed 
Knew 74% 
Learned  15% 
Still struggling after counseling 11% 
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6.0  DISCUSSION 
The NCAA approval of mandatory testing for sickle cell carrier status in April 2010 created an 
opportunity for our program to extend our services to local Pittsburgh universities.  Our program 
was successful in offering testing services to student athletes at two local Pittsburgh universities: 
University of Pittsburgh and Duquesne University.  Contact was successfully initiated and 
maintained with the Athlete Departments at these Division 1 universities.  During the study, our 
program complied with the NCAA’s ruling to ensure that the athletes and the respective Athletic 
Departments were aware of the student athletes’ carrier status in a timely fashion, prior to their 
eligibility to practice.   
Our program was also effective at providing genetic counseling to the student athletes, 
prior to their testing for sickle cell trait.  The students were provided with educational material 
regarding sickle cell disease, sickle cell trait, and the potential complications associated with 
sickle cell trait related to exercise.  Guidelines were provided that illustrated preventative 
measures during times of extreme exercise.  Along with this information, the reproductive 
consequences related to sickle cell disease and sickle cell trait were covered.   
The main goal of this study was encased within the third aim of this study.  The main 
objective of this study was to provide the student athletes with questionnaires, one prior to 
genetic counseling and testing, and one immediately following testing.  These questionnaires 
were collected in an attempt to gain knowledge of the effectiveness of the genetic counseling 
  46 
prior to sickle cell trait testing.  The pre-counseling questionnaire allowed us to gain a better 
understanding of what the student athletes’ knowledge of sickle cell disease and sickle cell trait, 
prior to any genetic counseling.    Based on the data from the pre-counseling questionnaire, the 
majority of the student athletes had a basic understanding of sickle cell disease and sickle cell 
trait.   
The next step in analysis involved comparing the pre- and post-counseling 
questionnaires, which allowed us to gain a better understanding of the effectiveness of the 
genetic counseling that was offered to the student athletes.  Based on the analysis of this data, it 
was clear that one question in particular (“Can a person with sickle cell trait ever develop the 
disease?”), seemed to confuse the student athletes.  T he question was meant to ask if an 
individual with sickle cell trait could ever develop sickle cell disease.  It  may have been 
interpreted a different way, such as asking if an individuals with sickle cell trait could ever 
develop symptoms that are associated with an exertional sickling event.  I believe this may be the 
case due to the fact that a number of student athletes changed their response from “no” to “yes” 
following the counseling session, at which time we discussed the symptoms associated with an 
exertional sickling event for individuals with sickle cell trait.  Due to this ambiguity of this 
particular question, future genetic counseling prior to sickle cell trait testing must clarify this 
information.  E mphasis needs to be placed on the difference between sickle cell disease and 
sickle cell trait, along with the complications that are associated with exercise and sickle cell 
trait.   
Aside from this single question of confusion, there still was not 100% knowledge of 
sickle cell disease and sickle cell trait.  Due to this evidence, genetic counseling is an important 
part of any genetic testing process.  Individuals, particularly student athletes, must be aware of 
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the testing they are undergoing, along with the impact the information will have on their life.  
For student athletes, not only does sickle cell trait testing have an impact on their athletic careers, 
but also on their reproductive futures.  Therefore, genetic counseling should be an essential part 
of the testing process among all student athletes complying with the NCAA ruling.   
6.1 FUTURE DIRECTION OF TESTING 
Much controversy surrounded the April 13, 2010 NCAA ruling mandating sickle cell trait testing 
for all Division I student athletes.  In previous years, sickle cell trait testing for student athletes 
was simply recommended, left up t o the discretion of individual programs.  Once mandated, 
many disputed the ruling, stating that it took away student athletes’ right to decide for themselves 
whether they wanted to undergo genetic testing or not.   
A similar event occurred at the University of California, Berkeley during the summer of 
2010.  The University of California, Berkeley decided to offer the freshman the opportunity to 
screen for three specific genes and called the project “Bring Your Genes to Cal”.92  Variants of 
these genes would provide the students with more information on t heir ability to absorb folic 
acid, their ability to tolerate alcohol, and their ability to metabolize lactose.93  All freshman were 
sent a DNA saliva kits and asked to turn them on a voluntary basis.  This program gained rapidly 
gained media attention and state health officials did end up ruling that this program violated state 
law due to the release of the test results to the students who volunteered their DNA.92  The 
controversy surrounding this program may set a bad precedent for the future direction of genetic 
testing.92 
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Other controversies surrounding the NCAA ruling included the concern for isolation of 
individuals at risk for being sickle cell trait carriers, along with those who tested positive for 
having sickle cell trait.  With the limited contact made between our program and the Athletic 
training staff at the University of Pittsburgh, some discussion occurred involving the treatment of 
student athletes with sickle cell trait.  Athletic trainers expressed their feelings that student 
athletes with sickle cell trait would not be treated any differently.  The mission of athletic 
trainers is to be aware of each individual student athletes’ abilities and limitations and to keep in 
mind what is best for each student athlete. 
A limitation of our study is that we did not have contact with any student athlete with 
sickle cell trait at the University of Pittsburgh or Duquesne University.  Having contact with a 
student athlete with sickle cell trait may have provided more insight on the impact the results had 
on those particular student athletes’ life and athletic career.   
Future plans include enrolling the Athletic Department Staff at the University of 
Pittsburgh in a questionnaire including questions surrounding the potential impact a positive 
result may have on a  student athlete, particularly dealing with how a student athlete may be 
treated by the staff, along with the impact it may have on an athletes future on the field and off.  
Additional future plans include more education for student athletes regarding the testing process.  
A fear in the public is that student athletes may not have a solid understanding of the intention of 
the testing process; they may feel pressured into taking the test or pressured into not taking the 
test.   Due to the public's fear that the testing may isolate a student athlete or lead to 
discrimination of student athletes with sickle cell trait, the student athletes themselves may also 
fear that and decide to opt out of testing.  I ndividuals with sickle cell trait may then go 
undetected and a sickling event may occur without warning, which may sadly lead to sudden 
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death in athletes.  Testing student athletes for sickle cell trait allow the athletic training and 
coaching staff to be aware of health concerns for those individuals, allowing for greater 
awareness of the warning signs of a sickling event.   
In conclusion, continuing this program, with the possibility of expanding to additional 
athletic programs, allows for better awareness and understanding of sickle cell trait and the 
impact on athletes.  Genetic counseling needs to play a larger role in various athletic programs 
across the country, which are offering sickle cell trait testing to their athletes.  The combination 
of the education and genetic counseling will ensure student athletes and the athletic staff have a 
solid understanding of sickle cell trait and impact on exercise.   
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APPENDIX A 
INSTITUTIONAL REVIEW BOARD CONSENT FORM 
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APPENDIX B 
QUESTIONNAIRE  
  54 
B.1 PRE-COUNSELING QUESTIONNAIRE 
Survey for Student Athletes        # __________ 
Sickle Cell Trait testing pre-counseling 
 
Today you will see a Genetic Counseling student to discuss Sickle Cell trait testing that is 
required by the NCAA for all prospective Division I Athletes.  You agree to be a part of a 
research study by f illing out this survey.  All answers will be confidential and you can 
refuse to answer any questions.  
 
 
Have you heard about sickle cell disease or sickle cell trait before today? 
 □ YES  □ NO 
 
Is there a difference between sickle cell trait and sickle cell disease? 
 □ YES  □ NO 
 
Can a person with sickle cell trait ever develop the disease? 
 □ YES  □ NO 
 
If both parents have sickle cell trait, is their chance of having a baby with disease 25%? 
 □ YES □ NO 
 
If you have sickle cell trait, can your brother or sister also have the trait? 
 □ YES  □ NO 
 
Can you “catch” sickle cell disease like you “catch” a cold? 
 □ YES  □ NO 
 
Which of the following best describes your ethnic background? 
 □ African American  
 □ American Indian or Eskimo 
 □ Asian or Pacific Islander 
 □ Latino/Hispanic 
 □ White/Caucasian 
 □ Some other ethnic background 
  Please explain: __________________________ 
 □ Prefer not to answer 
  55 
B.2 POST-COUNSELING QUESTIONNAIRE 
Survey for Student Athletes        # __________ 
Sickle Cell Trait testing follow-up 
 
Today you were seen by a Genetic Counseling student to discuss Sickle Cell trait testing 
that was required by the NCAA for all prospective Division I Athletes.  You agree to be a 
part of a research study by filling out this survey.  All answers will be confidential and 
you can refuse to answer any questions.  
 
Have you heard about sickle cell disease or sickle cell trait before your physical? 
 □ YES  □ NO 
 
Was it clear that there is a difference between sickle cell trait and sickle cell disease? 
 □ YES  □ NO 
 
Can a person with sickle cell trait ever develop the disease? 
 □ YES  □ NO 
 
If both parents have sickle cell trait, is their chance of having a baby with disease 25%? 
 □ YES □ NO 
 
If you have sickle cell trait, can your brother or sister also have the trait? 
 □ YES  □ NO 
 
Can you “catch” sickle cell disease like you “catch” a cold? 
 □ YES  □ NO 
 
Did you feel anxious before meeting with the genetic counselor today? 
Rating: 0 (not anxious) 1 (somewhat worried)  2(very anxious/concerned) 
 
Did the genetic counselor answer your questions to your satisfaction? 
 □ YES  □ NO 
 Any additional comments? __________________________________________ 
 ________________________________________________________________  
 
Did you have blood drawn for the testing at your physical? 
 □ YES  □ NO  
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Did you tell siblings or other family members you were getting testing done today? 
 □ YES  □ NO  
 
Was anyone upset that you were having testing done? 
 □ YES  □ NO  
 Please explain: ____________________________________________________ 
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APPENDIX C 
EDUCATIONAL MATERIALS PROVIDED TO STUDENT ATHLETES  
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APPENDIX D 
PRESENTATION GIVEN TO THE ATHLETIC ADMINISTRATORS, TRAINERS, AND 
COACHES AT THE UNIVERSITIES
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